Phosphoric Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRB1 ADRB2 ADRB3 CYP11B1 DPP4 FGFR1 FGFR2 FGFR3 FGFR4 HRH1 JAK1 JAK2 JAK3 KCNA1 KCNA10 KCNA2 KCNA3 KCNA4 KCNA5 KCNA6 KCNA7 KCNB1 KCNB2 KCNC1 KCNC2 KCNC3 KCNC4 KCND1 KCND2 KCND3 KCNF1 KCNG1 KCNG2 KCNG3 KCNG4 KCNH1 KCNH2 KCNH3 KCNH4 KCNH5 KCNH6 KCNH7 KCNH8 KCNQ1 KCNQ2 KCNQ3 KCNQ4 KCNQ5 KCNS1 KCNS2 KCNS3 KCNV1 KCNV2 KDR KIT NA OPRD1 OPRK1 OPRM1 P PDGFRB PIK3CD SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SMO TYK2 pol rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

	gene	UniProt	supporting neighbours	confidence
▸	FGFR4 known ✓	P22455	1/20	0.30

▸	LMNA	P02545	2/20	0.39

▸	ALDH1A1	P00352	3/20	0.37

▸	CA2	P00918	2/20	0.35

▸	TSHR	P16473	4/20	0.33

▸	ALOX15	P16050	1/20	0.33

▸	CA1	P00915	1/20	0.33

▸	CA9	Q16790	1/20	0.33

▸	PEPD	P12955	1/20	0.32

▸	MEN1	O00255	1/20	0.32

▸	HPGD	P15428	1/20	0.32

▸	BLM	P54132	1/20	0.32

▸	KMT2A	Q03164	1/20	0.32

▸	TDP1	Q9NUW8	1/20	0.32

▸	MMP2	P08253	1/20	0.30

▸	MMP3	P08254	1/20	0.30

▸	MMP8	P22894	1/20	0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Phosphoric Acid SCHEMBL28334070	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL28405846	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL28992572	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL1075962	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL9397372	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL23630620	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL29255680	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL3818781	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15
Phosphoric Acid SCHEMBL1574062	0.89	—	—
Phosphoric Acid SCHEMBL4553439	0.89	CA2 (0.43)	LMNAALDH1A1CA2TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-2731606-A1	GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	Allergan, Inc. (US)	2014-05-21	—	—	EP	disclosed
US-20130079379-A1	GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	ALLERGAN, INC. (US)	2013-03-28	—	—	US	disclosed
WO-2013010032-A1	GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	ALLERGAN, INC. (US)	2013-01-17	—	—	WO	disclosed
CN-1154133-C	Electrolytic solution for capacitor and capacitor	��ѧ��ʽ��	2004-06-16	—	—	CN	disclosed
EP-0902446-A2	Electrolytic solution for capacitor and capacitor	Mitsui Chemicals, Inc. (JP)	1999-03-17	—	—	EP	disclosed
CN-1211054-A	Electrolytic solution for capacitor and capacitor	MITSUI CHEMICALS INC (JP)	1999-03-17	—	—	CN	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20130079379-A1	GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE	CUTA, PDE3A, PTGIS	FGFR4 4192/4885LMNA 2853/4885ALDH1A1 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.